Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
47 studies found for:    " January 05, 2011":" February 04, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" January 05, 2011":" February 04, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated Lenalidomide in Kaposi Disease Associated With HIV Infection
Condition: HIV Infection Associated Kaposi Disease
Intervention: Drug: Lenalidomide
2 Completed Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis
Conditions: Human Immunodeficiency Virus;   Hepatitis C
Intervention: Drug: Raltegravir 400 mg/12hours
3 Withdrawn A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572;   Drug: GSK2248761
4 Recruiting Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
Conditions: HIV Infection;   Hepatitis C
Interventions: Drug: Anti-HIV Agents;   Drug: raltegravir;   Drug: Emtricitabine and tenofovir disoproxil fumarate
5 Unknown  Risk Taking Behaviour in MSM and the Denial of Sexually Transmitted Diseases and HIV
Conditions: MSM;   HIV Infections;   Risky Behaviors
Intervention:
6 Completed Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine
Condition: HIV Infections
Intervention: Biological: CN54gp140 glycoprotein-hsp70 conjugate vaccine
7 Completed
Has Results
Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination
Conditions: HIV;   Rabies
Intervention: Biological: rabies vaccines on day 0 and 3
8 Active, not recruiting Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients
Condition: HIV
Intervention: Drug: MVC/RAL/FTC/TDF followed by Maraviroc/Raltegravir
9 Completed Web-Based Middle School HIV Prevention Curricula: Aspiring for Reach and Impact
Conditions: HIV;   Sexually Transmitted Diseases
Intervention: Behavioral: It's Your Game Tech
10 Completed Electronic Intervention for HIV Medication Adherence
Condition: HIV
Intervention: Behavioral: Life Steps for Medication Adherence
11 Completed Rwanda Selenium Supplementation Clinical Trial
Condition: HIV
Interventions: Dietary Supplement: Selenium;   Other: Placebo
12 Completed Comparing the PrePex™ Device to Surgical Circumcision for Rapid Scale Up of Male Circumcision in Resource Limited Setting
Condition: HIV
Interventions: Device: PrePex™ device for adult male circumcision;   Procedure: Surgical circumcision
13 Completed The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1
Condition: HIV Infection
Intervention: Drug: Efavirenz
14 Completed The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)
Condition: HIV Infection
Intervention: Drug: Efavirenz
15 Completed Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.
Condition: HIV Infection
Intervention: Drug: TMC278LA
16 Unknown  Ethnicity Data in HIV Positive Men Who Have Sex With Men
Condition: HIV Infections
Intervention:
17 Completed TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir
Condition: HIV Infections
Interventions: Drug: TMC278;   Drug: Raltegravir
18 Completed
Has Results
Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM)
Conditions: HIV Infections;   Episodic Substance Use
Interventions: Behavioral: Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC);   Behavioral: Standard HIV testing with information only
19 Completed Microbicide Safety and Acceptability in Young Men
Conditions: High Risk MSM;   HIV Negative;   18-30 Years of Age
Interventions: Other: HEC Placebo Gel;   Drug: Tenofovir 1% Gel
20 Unknown  Modified Dose and Schedule of Recombinant Hepatitis B Vaccination in HIV-infected Adult Subjects
Condition: HIV Infection
Intervention: Biological: Hepavax-Gene

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years